CNS Pharmaceuticals Berubicin Trial is On Schedule to Commence in March 2021
Potentially pivotal study evaluating efficacy of Berubicin in the treatment of adult Glioblastoma Multiforme (GBM), one of the most aggressive types of brain cancer
News provided by
Share this article
(NASDAQ: CNSP) ( CNS or the Company ), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today indicated that the clinical program for Berubicin is on track to start enrolling patients in March 2021. CNS lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to cross the blood-brain barrier. It is in development for the treatment of a number of serious brain and CNS oncology indications.
UIC researchers find new biomarker for active sarcoidosis
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Combination therapy produces clinical benefit for early stage non-small cell lung cancer
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Date Time
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas MD Anderson Cancer Center published the study results today in Nature Medicine.
The NEOSTAR trial tested combined neoadjuvant therapy of nivolumab plus ipilimumab, as well as neoadjuvant nivolumab monotherapy in patients with operable NSCLC. The trial met its prespecified primary endpoint efficacy threshold in the combination arm, with eight of 21 treated patients (38%) achieving major pathological response, defined as ≤10% viable tumor at surgery. MPR has been show